The second phase 3 trial of laquinimod, known as
the BRAVO trial, included 1,106 patients with RRMS.
That trial consisted of a laquinimod arm, a placebo
arm, and a rater-blinded comparator arm of interferon
beta-1a. The trial failed to meet the primary end point
of relapse rate reduction. It was determined that the
baseline MRI characteristics of the treated and placebo
groups were different, which may have accounted for
the missed end point. After adjusting for the differences,
the results were statistically significant, with a
21% reduction in relapses (p = .26), a 33.5% decrease
in risk of disability progression (p = .044), and a
27.5% reduction in brain volume loss (p G .0001;
Vollmer, 2011).
S